Biovista Inc. – Product Pipeline Review – Q1 2011
Reference Code: GMDHC1113CDB
Publication Date: MAR 2011
Biovista Inc. – Product Pipeline Review – Q1 2011 GMDHC1113CDB / Published MAR 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Biovista Inc. – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 3
List of Figures 3
Biovista Inc. Snapshot 4
Biovista Inc. Overview 4
Key Information 4
Key Facts 4
Biovista Inc. – Research and Development Overview 5
Key Therapeutic Areas 5
Biovista Inc. – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Biovista Inc. – Pipeline Products Glance 9
Biovista Inc.–Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Biovista Inc. – Drug Profiles 10
BVA-101 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
BVA-201 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
BVA-301 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
BVA-601 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Biovista Inc. – Pipeline Analysis 14
Biovista Inc. – Pipeline Products by Therapeutic Class 14
Biovista Inc. – Pipeline Products by Route of Administration 15
Biovista Inc. – Pipeline Products by Molecule Type 16
Biovista Inc. – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Sep 09, 2009: Biovista Announces Positive Efficacy Results In A Pre-Clinical Trial Of BVA-201 For Multiple Sclerosis 18
Jun 23, 2009: Biovista Inc. Announces Positive Efficacy Results In A Pre-Clinical Trial Of Its BVA-601 Drug For Epilepsy 18
Apr 02, 2009: Biovista Inc. Announces Positive Efficacy Results In A Pre-Clinical Trial Of BVA-101 For Multiple Sclerosis 19
Appendix 20
Methodology 20
Coverage 20
Biovista Inc. – Product Pipeline Review – Q1 2011 GMDHC1113CD